DAPAONE S 10/100

Distributor inventory

Type 2 diabetes mellitus to improve blood sugar control (as an add-on to diet and exercise), especially when dual therapy is required

Dapagliflozin is an SGLT2 inhibitor that increases urinary glucose excretion by reducing glucose reabsorption in the kidneys. Sitagliptin is a DPP-4 inhibitor that increases incretin levels, enhancing insulin release and reducing glucagon in a glucose-dependent manner.

Take as prescribed by the doctor, usually once daily by mouth. Can be taken with or without food; take at the same time each day and swallow whole with water. Maintain adequate hydration and follow diet/exercise advice.

Genital fungal infection, urinary tract infection, increased urination, thirst, headache, nasopharyngitis, nausea, diarrhea, dizziness

Not for type 1 diabetes or diabetic ketoacidosis. Risk of dehydration and low blood pressure; drink fluids and use caution in elderly or those on diuretics. SGLT2 inhibitors can rarely cause ketoacidosis (even with near-normal sugar), serious urinary infections, and Fournier’s gangrene—seek urgent care if symptoms occur. Monitor kidney function; effectiveness reduces with significant renal impairment and may not be recommended at low eGFR. Sitagliptin may rarely cause pancreatitis or severe joint pain; stop and seek medical advice if severe abdominal pain occurs. Risk of hypoglycaemia increases if used with insulin or sulfonylureas; dose adjustment may be needed.

Insulin and sulfonylureas (increased hypoglycaemia risk), diuretics (increased dehydration/hypotension risk), rifampicin and other strong enzyme inducers (may reduce sitagliptin exposure), digoxin (sitagliptin may increase levels—monitor), alcohol (increases dehydration/ketoacidosis risk)

Store below 25°C in a dry place, protected from light and moisture. Keep in original blister pack and out of reach of children.

Qtern 10/100 Tablet, Dapavel S 10/100 Tablet, Dapa-Sita 10/100 Tablet, Dapary-S 10/100 Tablet, Dapazo-S 10/100 Tablet